Biologics for IBD: What to Expect With Crohn's and Colitis

Biologics for IBD: What to Expect With Crohn's and Colitis

← Patient Education

Biologics for IBD are medicines made from living cells that block specific signals the immune system uses to drive inflammation in Crohn's disease and ulcerative colitis. For many people with moderate to severe disease, they are now a main treatment rather than a last resort. This page explains what biologics are, how the main types differ, what happens before and after the first dose, and how a gastroenterologist decides whether one is working, based on the American College of Gastroenterology (ACG) guidelines for Crohn's disease, ulcerative colitis, and preventive care in IBD, all published in 2025.

This article is general education, not medical advice. No dose information is given here, and the right medicine for you depends on your disease, your history, and a conversation with your gastroenterologist.

What biologics for IBD are

Inflammatory bowel disease (IBD) is a long-term condition in which the immune system keeps the lining of the digestive tract inflamed. Older treatments such as steroids calm the immune system broadly. Biologics are proteins, usually antibodies, designed to block one target in the chain of signals that produces the inflammation. Because they are large proteins, they cannot be taken as a pill. They are given either through an IV infusion or as an injection under the skin.

Biologics belong to a wider group the guidelines call advanced therapies. That group also includes two kinds of oral pills, JAK inhibitors and S1P receptor modulators, which are small-molecule drugs rather than biologics. They are mentioned below where the guidelines place them alongside biologics, but this page is mainly about biologics.

Who is offered biologics for IBD

Both 2025 ACG guidelines tie biologics to moderately to severely active disease, and both push them earlier than they were used in the past.

Crohn's disease

The ACG Crohn's disease guideline suggests against requiring a person to fail conventional therapy before starting an advanced therapy. In other words, a person does not have to "use up" steroids or older immune-modifying medicines first. The guideline describes a randomized trial in newly diagnosed Crohn's disease in which early combined treatment with infliximab and an immunomodulator led to steroid-free and surgery-free remission at 48 weeks in 79% of patients, compared with 15% in a step-by-step approach. It also notes that anti-TNF biologics appear to work better when started within 2 years of disease onset, and it lists younger age at diagnosis, disease in the ileum, extensive disease, and large or deep ulcers on endoscopy as risk factors for the disease getting worse.

Ulcerative colitis

The ACG ulcerative colitis guideline says prognosis should guide the choice of therapy as much as how active the inflammation is right now. A person with mild to moderate colitis who has several risk factors for hospitalization or surgery should be treated with therapies meant for moderate to severe disease. Factors the guideline links to a higher chance of colectomy include extensive colitis, deep ulcers on endoscopy, a need for systemic steroids, diagnosis before age 30, elevated blood markers of inflammation, and a prior hospitalization for colitis. A person who does not respond to, or cannot tolerate, the standard first-line medicine for mild colitis (5-ASA, such as mesalamine) should be treated as having moderate to severe disease.

The guideline also says the amount of colon involved should not limit access to advanced therapies. A person with moderate to severe colitis confined to the rectum should have the same options as someone with more extensive disease.

The main types of biologics for IBD

The guidelines group biologics by the immune signal each one blocks. Generic names are used here. Several are also available as biosimilars, which are described further down.

Anti-TNF biologics

Anti-TNF medicines block tumor necrosis factor, one of the main drivers of inflammation in IBD. For Crohn's disease, the ACG recommends infliximab, adalimumab, and certolizumab pegol for inducing and maintaining remission. For ulcerative colitis, it recommends infliximab, adalimumab, and golimumab. The UC guideline calls infliximab the preferred anti-TNF therapy for moderate to severe ulcerative colitis, and both guidelines recommend combining infliximab with a thiopurine (an older immune-modifying pill) when infliximab is started in people who have not taken either before. Infliximab is given as an IV infusion for its starting doses and can then be continued by IV or by injection under the skin. The others are injections.

Vedolizumab

Vedolizumab blocks a protein that immune cells use to travel into the lining of the gut, so its effect is focused on the digestive tract. The ACG recommends it for both Crohn's disease and ulcerative colitis. In a head-to-head trial described in the UC guideline, vedolizumab outperformed adalimumab for clinical remission at 52 weeks (31.3% vs 22.5%), and the guideline recommends vedolizumab over adalimumab for moderate to severe ulcerative colitis. Starting doses are given by IV infusion, and maintenance can be by IV or injection.

Interleukin-12/23 and interleukin-23 blockers

Ustekinumab blocks two immune signals, interleukin-12 and interleukin-23. A newer group, guselkumab, mirikizumab, and risankizumab, blocks interleukin-23 alone. The ACG recommends all four for inducing and maintaining remission in both Crohn's disease and ulcerative colitis. For Crohn's disease in people who have already been on an anti-TNF medicine, the ACG suggests risankizumab over ustekinumab. The UC guideline notes that comparable head-to-head data do not yet exist for ulcerative colitis.

Where the oral advanced therapies fit

Tofacitinib and upadacitinib (JAK inhibitors) and ozanimod and etrasimod (S1P receptor modulators) are pills, not biologics. The ACG recommends JAK inhibitors and S1P modulators for moderate to severe ulcerative colitis, and upadacitinib for Crohn's disease in people who have already been exposed to an anti-TNF medicine. Your gastroenterologist may discuss these alongside biologics.

How a gastroenterologist chooses among biologics for IBD

The UC guideline is direct about the limits here: there are no validated tests that predict which medicine an individual will respond to, and the comparative evidence is thin. Choice is based on general principles and a shared decision with the patient. The factors the guidelines name include:

  • Which disease and how severe. Not every biologic is approved or recommended for both Crohn's disease and ulcerative colitis, or for every pattern of disease.
  • Fistulas. For Crohn's disease with fistulas around the anus, the ACG recommends infliximab and suggests adalimumab, vedolizumab, ustekinumab, or upadacitinib.
  • Infection risk. The UC guideline says some people at higher risk of infection may benefit from vedolizumab or an interleukin-23 blocker over more broadly immune-suppressing options.
  • Other conditions. Joint or skin disease linked to IBD can steer the choice toward a medicine that treats both. The Crohn's guideline lists prior demyelinating disease such as multiple sclerosis, congestive heart failure, and a history of lymphoma or other cancers as reasons for added caution with anti-TNF medicines.
  • Treatment history. The UC guideline notes that response and remission rates are higher with a first advanced therapy than after one or more have failed.
  • Pregnancy plans. The Crohn's guideline states anti-TNF medicines are safe to use during preconception planning, pregnancy, and after delivery. Our page on digestive problems in pregnancy covers the AGA's advice to continue biologics throughout pregnancy.
  • How it is given. Some people prefer an injection at home every few weeks. Others prefer a less frequent infusion given by a nurse. Both are reasonable, and your gastroenterologist can explain which formats each medicine comes in.

Screening before starting biologics for IBD

Because biologics change how the immune system responds, the ACG Crohn's guideline calls pretreatment screening for infections and laboratory abnormalities required. The main steps are:

  • Tuberculosis. Testing for latent and active tuberculosis before anti-TNF therapy, along with questions about exposure risk. A blood test called an interferon-gamma release assay is preferred for people who received the BCG vaccine. If latent tuberculosis is found, treatment for it begins several weeks before the anti-TNF medicine.
  • Hepatitis B. A three-part hepatitis B blood panel before most advanced therapies, because immune-suppressing medicines can reactivate a hepatitis B infection. People who are not immune are vaccinated, ideally before the biologic starts. People who carry the virus start antiviral medicine first. Our page on chronic hepatitis B and C explains these blood tests.
  • Vaccines. The ACG preventive care guideline says adults with IBD should get age-appropriate vaccines before immune-modifying therapy when possible, but that vaccination should not delay needed treatment.

Vaccines and biologics for IBD

The ACG preventive care guideline, published in July 2025, says adults on immune-modifying therapy should not receive live vaccines. Examples named in the Crohn's guideline include measles-mumps-rubella, yellow fever, the nasal flu vaccine, and the chickenpox vaccine. Nonlive vaccines are safe in people with IBD. The preventive care guideline advises:

  • An annual flu shot for all adults with IBD, using the injected vaccine, not the nasal spray, for anyone on immune-modifying therapy
  • The two-dose recombinant shingles vaccine for adults 19 and older on, or about to start, immune-modifying therapy, and for all adults 50 and older with IBD
  • A pneumococcal vaccine (PCV20 or PCV21) for adults 50 and older, and for adults 19 to 49 on immune-modifying therapy, who have not had one before
  • Hepatitis B vaccination for adults with IBD who are not immune
  • A check of chickenpox immunity before immune-modifying therapy begins

Household members can still receive most live vaccines, with certain precautions. Bring your vaccination records to the visit where a biologic is discussed, or ask your primary care physician to send them.

What starting biologics for IBD is like

Treatment is described in two phases. Induction is the first few doses, given close together, to bring inflammation under control. Maintenance is the ongoing schedule after that, meant to keep the disease in remission. Many biologics start with IV induction doses and then switch to injections for maintenance. The ACG UC guideline considers injected infliximab and vedolizumab equivalent to standard IV maintenance, though it says equivalence for induction has not been firmly established.

How quickly a biologic works varies. The Crohn's guideline notes that anti-TNF medicines can start working within the first 2 weeks. Response time varies by medicine and by person, which is why the guidelines build in a formal check rather than judging by the first few days.

If you are prescribed a biologic that is given by infusion, ask your care team where infusions are given and how long a visit takes. If it is an injection, you will usually be taught how to give it at home. Insurance approval is often needed before the first dose, which can add time.

How response to biologics for IBD is checked

Both guidelines set targets beyond feeling better. The UC guideline recommends treating to achieve endoscopic improvement, meaning the inflammation seen on colonoscopy has resolved or nearly resolved, because that raises the chance of lasting steroid-free remission and lowers the risk of hospitalization and surgery. It notes that symptoms alone are not a reliable measure, since healing can lag behind symptoms and many people have inflammation without symptoms.

  • Timing. The UC guideline says any treatment should be assessed at a defined point, 6 to 12 weeks after it starts, for efficacy and safety. The Crohn's guideline aims for clinical and lab response within 12 weeks.
  • Stool tests. The ACG recommends fecal calprotectin, a stool test for gut inflammation, to assess response, check a suspected flare, and monitor during maintenance.
  • Blood tests and drug levels. If an anti-TNF medicine stops working, the ACG advises measuring the drug level in the blood and checking for antibodies against the drug, to tell whether the dose should be adjusted or the medicine changed.
  • Colonoscopy. Endoscopy confirms healing. For people with long-standing colitis, colonoscopy also serves a cancer-prevention role, explained on our page about colonoscopy with ulcerative colitis.

When a biologic stops working

The UC guideline reports that up to one-fifth of people do not respond to an anti-TNF medicine at first, and another 10% to 15% lose response each year after an initial benefit. Low drug levels, antibodies against the drug, an infection, or overlapping non-inflammatory symptoms can all be the cause, so the guideline advises a careful evaluation before switching. If an anti-TNF medicine fails despite adequate drug levels, the guideline advises moving to a different class rather than cycling to another anti-TNF.

Side effects and risks of biologics for IBD

The ACG Crohn's guideline describes the safety profile of anti-TNF medicines as generally favorable, citing a meta-analysis of 21 trials with 5,356 patients that found no increase in serious infection, cancer, or death compared with placebo. It adds two cautions: one-year trials may be too short to detect rarer problems, and infections can still occur, so routine lab monitoring and counseling about side effects are part of care. For ustekinumab and risankizumab, the long-term trials it describes found no increased risk of opportunistic infections, tuberculosis, or cancer. Vedolizumab's gut-focused action gives it a more favorable safety profile than an older medicine in its class.

Combining a biologic with a thiopurine needs a separate conversation. The Crohn's guideline notes a higher lymphoma risk with thiopurines, especially in older people and with longer use, and a rare but increased risk of a specific lymphoma, mainly in younger men, on combined anti-TNF and thiopurine therapy. That is why combination therapy is individualized.

The ACG preventive care guideline also suggests annual skin checks for melanoma for everyone with IBD, whether or not they take a biologic.

Contact your care team promptly if you develop a fever, signs of infection, a new rash, or a reaction during or after an infusion or injection. Do not stop a biologic on your own. Talk with your gastroenterologist first.

Biosimilars and insurance for biologics for IBD

A biosimilar is a near-identical version of an existing biologic, similar to how a generic relates to a brand-name pill. The ACG UC guideline states that biosimilars to anti-TNF medicines and to ustekinumab are acceptable substitutes for the originals, that switches should not be delayed, and that patients and clinicians should be told about such changes. The Crohn's guideline says biosimilar infliximab, adalimumab, and ustekinumab work for starting and maintaining treatment, and that data support switching to biosimilar infliximab or adalimumab during stable maintenance.

Cost and coverage shape access. The UC guideline notes that insurers use step therapy (requiring cheaper medicines to fail first), denials, higher copays, and frequent reauthorizations, and it states that third-party payers should not come between patients and their care team. Prior authorization paperwork is a normal part of starting a biologic. Ask your care team what your plan requires, and contact your insurer about your share of the cost.

Diet, stress, and biologics for IBD

Diet can help with symptoms and nutrition, but it does not replace medicine for moderate to severe IBD. Our page on the IBD diet covers what the AGA's guidance supports. IBD can also cause iron deficiency anemia, which may need its own treatment even after inflammation improves. The ACG preventive care guideline advises screening everyone with Crohn's disease or ulcerative colitis for depression and anxiety at the start of care and once a year after that.

Questions to ask about biologics for IBD

  • Which type of biologic are you recommending, and why that one for my disease?
  • Is it an infusion or an injection, and how often after the starting doses?
  • Which screening tests and vaccines do I need first?
  • Will I take it alone or with another medicine?
  • When and how will we check whether it is working?
  • What side effects should make me call right away?
  • Is a biosimilar an option, and what does my insurance require?
  • How does this fit with plans for pregnancy, surgery, or travel?

IBD care in Northern Virginia

Our gastroenterologists diagnose and manage Crohn's disease and ulcerative colitis for patients across Arlington, Annandale, Fairfax, Falls Church, Alexandria, and the surrounding area. If you are newly diagnosed, still on steroids, or wondering whether your current treatment is the right fit, a visit can help sort out your options. If you have not been seen before, our page on your first gastroenterologist visit explains what to bring, including records from past colonoscopies and medicines you have tried.

We see patients at our Arlington office at 1715 N George Mason Drive, adjacent to VHC Health, and our Annandale office at 3299 Woodburn Road in the Woodburn Medical complex. To schedule a visit, call Arlington at (703) 522-7476 or Annandale at (703) 560-6106, or learn more at gcofnova.com.

Frequently asked questions about biologics for IBD

Do I have to try other medicines before a biologic?

Not necessarily. The ACG 2025 Crohn's guideline suggests against requiring conventional therapy to fail before an advanced therapy is started. The ACG ulcerative colitis guideline says people with mild to moderate colitis and several risk factors for hospitalization or surgery should be treated with therapies for moderate to severe disease. Insurance plans may still require step therapy.

Are biologics for IBD given as infusions or shots?

Both, depending on the medicine. Infliximab and vedolizumab start with IV infusions and can be continued by IV or injection. Adalimumab, certolizumab pegol, and golimumab are injections. Several interleukin-blocking biologics start with an IV dose and continue as injections. Your gastroenterologist can explain the format for the medicine you are offered.

What tests are needed before starting a biologic?

The ACG Crohn's guideline calls for testing for latent and active tuberculosis before anti-TNF therapy and a hepatitis B blood panel before most advanced therapies. People who are not immune to hepatitis B are vaccinated, and other age-appropriate vaccines are ideally given before treatment starts, without delaying needed therapy.

Can I get vaccines while taking a biologic?

Yes for nonlive vaccines, which the ACG preventive care guideline says are safe in people with IBD. These include the injected flu shot, the recombinant shingles vaccine, pneumococcal vaccines, and hepatitis B vaccine. Live vaccines, such as MMR, yellow fever, chickenpox, and the nasal flu vaccine, should be avoided while on immune-modifying therapy.

How long does it take a biologic to work for Crohn's or colitis?

It varies by medicine and person. The ACG notes anti-TNF medicines can begin working within 2 weeks. The ulcerative colitis guideline advises checking any new treatment 6 to 12 weeks after it starts, and the Crohn's guideline aims for clinical and lab response within 12 weeks, using stool tests, blood tests, and sometimes colonoscopy.

Is a biosimilar as good as the original biologic?

The ACG 2025 ulcerative colitis guideline states that biosimilars to anti-TNF medicines and to ustekinumab are acceptable substitutes for the originals. The Crohn's guideline says biosimilar infliximab, adalimumab, and ustekinumab work for starting and maintaining treatment, and that switching during stable maintenance is supported by data for infliximab and adalimumab.

This article is for general education and is not medical advice. Medicine choices, schedules, and screening described here are general guideline recommendations, and your own treatment depends on your disease, your history, and your physician's judgment. Talk with a qualified gastroenterologist about your symptoms, diagnosis, and treatment options.

About us



We would like to welcome you to the Gastroenterology Center of Northern Virginia, Ltd. We appreciate the opportunity to participate in your care. It is our sincere desire to provide you with the highest quality and most comprehensive services in the diagnosis, treatment and management of various digestive conditions.

Arlington Address


1715 N George Mason Dr, Suite 403, Arlington, VA 22205
(adjacent to VHC Health, Zone C,
Parking C )
Phone: (703) 522-7476
Fax: (703) 528-4209
Office hours:
Monday – Thursday 8:30 am – 5:00 pm
Friday 8:30 am – 4:30 pm

Annandale Address


3299 Woodburn Road, Suite 220 Annandale, VA 22003
(second building in the Woodburn Medical complex)
Phone: (703) 560-6106
Fax: (703) 204-1968
Office hours:
Monday - Thursday 8:30 am – 5:00 pm
Friday 8:30 am – 4:30 pm
Copyright - 2019 Gastroenterology Center of Northern Virginia. All rights reserved.